Mazdutide: yaiku tirzepatide‑like weight loss peptide?

Posted by grace_sleepnerd in Research & News - 1 points, 0 comments.

I just finished a paper on the warum of Mazdutide, the new dual GLP‑1/Glucagon agonist. The authors ran a phase II trial with 80 obese volunteers and got up to an 18% weight loss after 16 weeks, which is on par with tirzepatide. They also noted a clear drop in liver fat content, which is a bonus for anybody worried about NASH.

For me, the dual action makes sense – GLP‑1 cuts appetite, glucagon just uppers energy expenditure. The dosing was once weekly, 3–9 mg, so it feels convenient, but the side‑effect profile is not trivialExperiences of nausea and occasional diarrhea show up in the reports, and a few folks mentioned injection site itching. I’m still skeptical about the long‑term safety profile, especially since we’re talking about a compound that hits two hormone pathways. I’m curious: have any of y’all seen anyone using it beyond the trial period, and what has been the real‑world response, both for staying on it and any hepatic changes?

Community discussion - research and educational context only. Not medical advice.